miR-3591-3p靶向P53对卵巢癌SKOV3/DDP细胞顺铂耐药的影响
该研究通过靶标预测和双荧光素酶实验验证miR-3591-3p靶向P53,并在SKOV3/DDP细胞及裸鼠移植瘤模型中观察敲低miR-3591-3p对顺铂耐药的影响。结果显示敲低miR-3591-3p可降低细胞存活率和IC50值、诱导凋亡并抑制肿瘤生长,而敲低P53可抑制上述效应。结论为miR-3591-3p靶向P53增强SKOV3/DDP细胞顺铂耐药。
要点
- 双荧光素酶实验证实miR-3591-3p与P53存在结合位点并靶向调控P53。
- 敲低miR-3591-3p可降低SKOV3/DDP细胞IC50值并增加凋亡率,增强顺铂效应。
- 敲低P53表达可抑制敲低miR-3591-3p对上述指标的改善作用。
核心结论
- miR-3591-3p靶向P53增强SKOV3/DDP细胞顺铂耐药。
研究设计与样本
- 体外研究:SKOV3/DDP细胞分为对照组、DDP组、anti-miR-3591-3p组、anti-miR-NC组、DDP+anti-miR-3591-3p组、DDP+anti-miR-NC组、DDP+anti-miR-3591-3p+sh-P53组、DDP+anti-miR-3591-3p+sh-NC组。
- 体内研究:裸鼠分为对照组、DDP组、anti-miR-3591-3p组、anti-miR-NC组、DDP+anti-miR-3591-3p组,皮下注射SKOV3/DDP细胞制备移植瘤模型。
- 方法包括靶标预测、双荧光素酶实验、CCK-8实验、流式细胞术、RT-qPCR和Western blot。
主要发现
- 过表达miR-3591-3p后野生型P53荧光素酶活性降低(P<0.05),突变型P53荧光素酶活性未见明显差异(P>0.05)。
- DDP组24、36、48 h IC50值分别为(21.26±2.95)mg/L、(17.38±1.93)mg/L和(13.76±1.46)mg/L,对照组分别为(41.06±4.39)mg/L、(36.15±3.46)mg/L和(29.87±1.39)mg/L;anti-miR-3591-3p组分别为(19.96±2.19)mg/L、(17.62±3.52)mg/L和(13.05±1.53)mg/L,anti-miR-NC组分别为(43.37±3.83)mg/L、(40.47±2.82)mg/L和(31.41±0.73)mg/L。
- DDP组细胞凋亡率为(27.00±2.00)%,对照组为(3.33±1.53)%;anti-miR-3591-3p组为(28.98±3.14)%,anti-miR-NC组为(4.05±1.96)%。
- DDP组14、21、28 d肿瘤体积分别为(284.26±24.51)mm3、(563.21±44.17)mm3和(741.32±72.01)mm3,对照组分别为(384.25±41.25)mm3、(840.32±71.27)mm3和(1 242.47±100.54)mm3;DDP组肿瘤质量为(0.85±0.15)g,对照组为(1.34±0.12)g;anti-miR-3591-3p组肿瘤质量为(0.88±0.14)g,anti-miR-NC组为(1.34±0.10)g。
- 敲低miR-3591-3p表达能够增强DDP对上述指标的影响(均P<0.05);敲低P53表达能够抑制敲低miR-3591-3p表达对上述指标的影响(均P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the effect of miR-3591-3p targeting P53 on cisplatin resistance of ovarian cancer (OC) SKOV3/DDP cells. Methods: Target prediction and dual luciferase assay were used to validate miR-3591-3p targeting P53. SKOV3/DDP cells were divided into control group, DDP group, miR-3591-3p knockdown group (anti-miR-3591-3p), miR-3591-3p knockdown control group (anti-miR-NC), cisplatin+miR-3591-3p knockdown group (DDP+anti-miR-3591-3p), cisplatin+control group (DDP+anti-miR-NC), cisplatin+miR-3591-3p knockdown+P53 knockdown group (DDP+anti-miR-3591-3p+sh-P53), cisplatin+miR-3591-3p knockdown+P53 knockdown control group (DDP+anti-miR-3591-3p+sh-NC). CCK-8 assay was used to detect cell survival rate and IC50 value; Flow cytometry were used to detect cell cycle and apoptosis; RT-qPCR was used to detect miR-3591-3p and P53 mRNA levels in cells; Western blot was used to detect P53, P-gp, MRP1, Ki-67, CyclinD1, Bcl-2, and Bax protein levels in cells. Nude mice were divided into control group, DDP group, miR-3591-3p knockdown group (anti-miR-3591-3p), miR-3591-3p knockdown control group (anti-miR-NC), and cisplatin+miR-3591-3p knockdown group (DDP+anti-miR-3591-3p). Subcutaneous injection of SKOV3/DDP cells was used to prepare transplanted tumor model. Tumor volume, mass, miR-3591-3p, P53 mRNA and protein levels in tumor tissue were detected. Results: MiR-3591-3p and P53 had binding sites. After overexpression of miR-3591-3p, wild-type P53 luciferase activity was decreased (P<0.05); However, there was no significant difference in the luciferase activity of mutant P53 (P>0.05). After DDP treatment or knockdown of miR-3591-3p expression, miR-3591-3p level in cells was decreased, the mRNA and protein levels of P53 were increased; the cell survival rate and IC50 value were decreased [DDP group 24, 36, 48 h IC50 (21.26±2.95)mg/L,(17.38±1.93)mg/L and (13.76±1.46)mg/L, control group (41.06±4.39)mg/L, (36.15±3.46)mg/L and(29.87±1.39)mg/L; anti-miR-3591-3p group 24,36,48 h IC50 (19.96±2.19)mg/L, (17.62±3.52)mg/L and (13.05±1.53)mg/L,anti-miR-NC group (43.37±3.83)mg/L, (40.47±2.82)mg/L and (31.41±0.73)mg/L], the proportion of S phase was decreased, the proportion of G0/G1 phase and cell apoptosis rate [DDP group (27.00±2.00)%, Control group (3.33±1.53)%; anti-miR-3591-3p group (28.98±3.14)%, anti-miR-NC group (4.05±1.96)%] were increased; P-gp, MRP1, Ki-67, CyclinD1, Bcl-2 protein levels were decreased, while Bax protein level was increased (all P<0.05). Knocking down miR-3591-3p could enhance the impact of DDP on the above indicators (all P<0.05). Knocking down P53 expression could inhibit the impact of miR-3591-3p deletion on the above indicators (all P<0.05). After DDP treatment or knockdown of miR-3591-3p, the tumor volume and weight of nude mice were decreased [DDP group 14,21,28 d volume (284.26±24.51)mm3,(563.21±44.17)mm3 and (741.32±72.01)mm3,control group (384.25±41.25)mm3, (840.32±71.27)mm3 and (1 242.47±100.54)mm3; anti-miR-3591-3p group 14,21,28 d volume (274.47±27.77)mm3, (584.68±61.14)mm3 and (815.24±73.19)mm3, anti-miR-NC group (355.47±46.84)mm3, (804.24±79.54)mm3 and (1 350.47±108.37)mm3; DDP group weight (0.85±0.15)g,control group (1.34±0.12)g; anti-miR-3591-3p group (0.88±0.14)g, anti-miR-NC group (1.34±0.10)g],miR-3591-3p level in tumor tissue was decreased, and the mRNA and protein levels of P53 were increased (all P<0.05); Knocking down miR-3591-3p could enhance the effect of DDP on the above indicators (all P<0.05). Conclusion: MiR-3591-3p targeting P53 enhances cisplatin resistance in SKOV3/DDP cells. 目的: 探讨miR-3591-3p靶向P53对卵巢癌顺铂(DDP)耐药细胞系(SKOV3/DDP)DDP耐药的影响。 方法: 靶标预测和双荧光素酶实验验证miR-3591-3p靶向调控P53。SKOV3/DDP细胞分为对照组、DDP组、敲低miR-3591-3p表达组(anti-miR-3591-3p)、敲低miR-3591-3p表达对照组(anti-miR-NC)、DDP+敲低miR-3591-3p表达组(DDP+anti-miR-3591-3p)、DDP+敲低miR-3591-3p表达对照组(DDP+anti-miR-NC)、DDP+敲低miR-3591-3p表达+敲低P53表达组(DDP+anti-miR-3591-3p+sh-P53)、DDP+敲低miR-3591-3p表达+敲低P53表达对照组(DDP+anti-miR-3591-3p+sh-NC)。细胞计数试剂盒8实验检测细胞存活率和半抑制浓度(IC50)值,流式细胞术检测细胞周期和细胞凋亡,实时荧光定量聚合酶链反应检测细胞中miR-3591-3p、P53 mRNA表达水平,Western blot检测细胞中P53、P-gp、多药耐药相关蛋白1(MRP1)、Ki-67、CyclinD1、Bcl-2、Bax蛋白表达水平。裸鼠分为对照组、DDP组、敲低miR-3591-3p表达组(anti-miR-3591-3p)、敲低miR-3591-3p表达对照组(anti-miR-NC)、DDP+敲低miR-3591-3p表达组(DDP+anti-miR-3591-3p)。采用皮下注射SKOV3/DDP细胞制备移植瘤模型,检测肿瘤体积、质量、肿瘤组织miR-3591-3p、P53 mRNA和蛋白表达水平。 结果: miR-3591-3p和P53存在结合位点,过表达miR-3591-3p后,野生型P53荧光素酶活性降低(P<0.05),而突变型P53的荧光素酶活性未见明显差异(P>0.05)。DDP处理或敲低miR-3591-3p表达后,miR-3591-3p水平降低,P53 mRNA和蛋白水平升高(均P<0.05),细胞存活率、IC50值[DDP组24、36、48 h IC50值分别为(21.26±2.95)mg/L、(17.38±1.93)mg/L和(13.76±1.46)mg/L,对照组分别为(41.06±4.39)mg/L、(36.15±3.46)mg/L和(29.87±1.39)mg/L;anti-miR-3591-3p组24、36、48 h IC50值分别为(19.96±2.19)mg/L、(17.62±3.52)mg/L和(13.05±1.53)mg/L,anti-miR-NC组分别为(43.37±3.83)mg/L、(40.47±2.82)mg/L和(31.41±0.73)mg/L]降低,S期细胞比例降低,G0/G1期细胞比例、细胞凋亡率[DDP组为(27.00±2.00)%,对照组为(3.33±1.53)%;anti-miR-3591-3p组为(28.98±3.14)%,anti-miR-NC组为(4.05±1.96)%]升高,P-gp、MRP1、Ki-67、CyclinD1、Bcl-2蛋白水平降低,Bax蛋白水平升高(均P<0.05);敲低miR-3591-3p表达能够增强DDP对上述指标的影响(均P<0.05);敲低P53表达能够抑制敲低miR-3591-3p表达对上述指标的影响(均P<0.05)。DDP处理或敲低miR-3591-3p表达后,裸鼠肿瘤体积[DDP组14、21、28 d肿瘤体积分别为(284.26±24.51)mm3、(563.21±44.17)mm3和(741.32±72.01)mm3,对照组分别为(384.25±41.25)mm3、(840.32±71.27)mm3和(1 242.47±100.54)mm3;anti-miR-3591-3p组14、21、28 d肿瘤体积分别为(274.47±27.77)mm3、(584.68±61.14)mm3和(815.24±73.19)mm3,anti-miR-NC组分别为(355.47±46.84)mm3、(804.24±79.54)mm3和(1 350.47±108.37)mm3]、肿瘤质量[DDP组(0.85±0.15)g,对照组(1.34±0.12)g;anti-miR-3591-3p组(0.88±0.14)g,anti-miR-NC组(1.34±0.10)g]减小,肿瘤组织中miR-3591-3p水平降低,P53 mRNA和蛋白升高(均P<0.05);敲低miR-3591-3p表达能够增强DDP对上述指标的影响(均P<0.05)。 结论: miR-3591-3p靶向P53增强SKOV3/DDP细胞DDP耐药。.
引用
- Zheng J, He J. [The effect of miR-3591-3p targeting P53 on cisplatin resistance in ovarian cancer SKOV3/DDP cells]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40534265. doi:10.3760/cma.j.cn112152-20240711-00285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。